References in periodicals archive ?
Decrease in serum adiponectin levels in response to treatment predicts good prognosis in acute decompensated heart failure. J Clin Hypertens (Greenwich) 2010; 12: 900-904, doi: 10.1111/j.1751-7176.2010.00368.x.
PIONEER-HF was a landmark, practice-changing, double-blind clinical trial in which 881 patients were randomized to initiation of sacubitril/valsartan (Entresto) or enalapril during hospitalization for acute decompensated heart failure. In the previously reported main outcome, 8 weeks after discharge the sacubitril/valsartan group had a 29% greater reduction in NT-proBNP (the N-terminal prohormone of brain natriuretic peptide) and a 42% lower rate of the composite clinical endpoint of cardiovascular death or heart failure rehospitalization than the enalapril group (N Engl J Med.
Abbreviations ADHF: Acute decompensated heart failure CHF: Congestive heart failure DPG: Diastolic pressure gradient FDA: Food and Drug Administration HF: Heart failure IHD: Implantable hemodynamic device IVC: Inferior vena cava LAP: Left atrial pressure LV: Left ventricle NYHA: New York Heart Association PA: Pulmonary artery PAdP: Pulmonary artery diastolic pressure PAsP: Pulmonary artery systolic pressure PCWP: Pulmonary capillary wedge pressure RAP: Right atrial pressure RV: Right ventricle VTR: Tricuspid regurgitation velocity.
High prevalence of renal dysfunction and its impact on outcome in 118 465 patients hospitalized with acute decompensated heart failure: A report from the ADHERE database.
Compared with other Asian patients, such as those enrolled in the Acute Decompensated Heart Failure Syndromes or Korean Acute Heart Failure Registry Studies,[sup][12],[13] AHF patients in our study presented with less hypertension.
Rationale and design of PRIMA II: a multicenter, randomized clinical trial to study the impact of in-hospital guidance for acute decompensated heart failure treatment by a predefined NT-PRoBNP target on the reduction of readmission and Mortality rAtes.
Saltzberg et al., "Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure," Journal of the American College of Cardiology, vol.
Delayed hospital presentation in acute decompensated heart failure: Clinical and patient reported factors.
Istaroxime is a first-in-class luso-inotropic agent under development for the treatment of acute decompensated heart failure. It possesses a unique dual mode of action, combining inotropic (myocyte contraction) and lusotropic (myocyte relaxation) effects.
Patient characteristics from a regional multicenter database of acute decompensated heart failure in Asia Pacific (ADHERE International-Asia Pacific).
SNOWMASS, COLO.--The primary treatment goal in patients hospitalized for acute decompensated heart failure is aggressive decongestion to get them feeling better and out of the hospital quicker --and the best way to achieve that is with high-dose loop diuretics administered intravenously at a dose equivalent to 2.5 times the previous oral dose, Dr.
Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol.
Full browser ?